anthrax
T2 Biosystems Gets FDA 510(k) Clearance for Biothreat Panel
The clearance allows the firm to immediately begin marketing an assay that simultaneously detects six biothreat pathogens directly from blood.
Despite recent struggles, the firm remains optimistic about its position as the first and only direct-from-blood sepsis test system.
Tangen Biosciences Receives Additional $3.3M From BARDA
The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
The Branford, Connecticut-based startup plans to seek US Food and Drug Administration clearance for and launch its instrument and first assays in 2021.